{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T04:13:44Z","timestamp":1782620024248,"version":"3.54.5"},"reference-count":112,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cld.2025.06.010","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T03:46:29Z","timestamp":1753847189000},"page":"781-797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Future Treatment Options for Managing Primary Sclerosing Cholangitis and Cholestatic Pruritus"],"prefix":"10.1016","volume":"29","author":[{"given":"Taranika Sarkar","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Vuppalanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2025.06.010_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41572-025-00600-x","article-title":"Primary sclerosing cholangitis","volume":"11","author":"Manns","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cld.2025.06.010_bib2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.5858\/arpa.2014-0229-RA","article-title":"Pathophysiology and diseases of the proximal pathways of the biliary system","volume":"139","author":"Nakanishi","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cld.2025.06.010_bib3","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2741\/e490","article-title":"Primary sclerosing cholangitis: etiopathogenesis and clinical management","volume":"4","author":"Gupta","year":"2012","journal-title":"Front Biosci (Elite Ed)"},{"key":"10.1016\/j.cld.2025.06.010_bib4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.23736\/S0026-4806.20.06604-5","article-title":"Prognostic value of perinuclear antineutrophil cytoplasmic antibodies in subjects with primary sclerosing cholangitis","volume":"113","author":"Guglielmi","year":"2022","journal-title":"Minerva Med"},{"key":"10.1016\/j.cld.2025.06.010_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112877","article-title":"PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC)","volume":"9","author":"Stinton","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2025.06.010_bib6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3109\/00365521.2013.825313","article-title":"Antineutrophil cytoplasmic antibodies in bile are associated with disease activity in primary sclerosing cholangitis","volume":"48","author":"Lenzen","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib7","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000452","article-title":"Unique bile acid profiles in the bile ducts of patients with primary sclerosing cholangitis","volume":"8","author":"Kayashima","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2025.06.010_bib8","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/gut.38.4.610","article-title":"Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis","volume":"38","author":"Broom\u00e9","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.cld.2025.06.010_bib9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.gie.2009.10.041","article-title":"Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment","volume":"71","author":"Gotthardt","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.cld.2025.06.010_bib10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.yasu.2009.02.015","article-title":"Primary sclerosing cholangitis: the role of extrahepatic biliary resection","volume":"43","author":"Tsai","year":"2009","journal-title":"Adv Surg"},{"key":"10.1016\/j.cld.2025.06.010_bib11","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1111\/j.1572-0241.1999.01364.x","article-title":"Four years experience with short term stenting in primary sclerosing cholangitis","volume":"94","author":"Ponsioen","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib12","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.010_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/hep.510270201","article-title":"Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study","volume":"27","author":"Bergquist","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.010_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","article-title":"Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study","volume":"102","author":"Tischendorf","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","article-title":"The natural history of small-duct primary sclerosing cholangitis","volume":"134","author":"Bj\u00f6rnsson","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.06.010_bib16","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1053\/jhep.2002.33202","article-title":"Small-duct primary sclerosing cholangitis: a long-term follow-up study","volume":"35","author":"Angulo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.010_bib17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.clinre.2011.10.007","article-title":"PSC, AIH and overlap syndrome in inflammatory bowel disease","volume":"36","author":"Trivedi","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib18","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/003655202760373434","article-title":"Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation","volume":"37","author":"Boberg","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2010.02.030","article-title":"In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival","volume":"53","author":"Rudolph","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib20","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1365-2036.2011.04822.x","article-title":"Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis","volume":"34","author":"Triantos","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2025.06.010_bib21","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"106","author":"Eaton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib22","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.010_bib23","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1365-2036.2011.04863.x","article-title":"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis","volume":"34","author":"Imam","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2025.06.010_bib24","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.010_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12876-023-02653-2","article-title":"PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis","volume":"23","author":"Trauner","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib26","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.cgh.2022.07.024","article-title":"Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-Week open-label extension in patients with PSC","volume":"21","author":"Trauner","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib27","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/liv.13110","article-title":"Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value","volume":"36","author":"de Vries","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2025.06.010_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2010.12.008","article-title":"Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis","volume":"43","author":"Stanich","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cld.2025.06.010_bib29","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis","volume":"11","author":"Lindstr\u00f6m","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib30","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/apt.16296","article-title":"Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis","volume":"53","author":"Mazhar","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2025.06.010_bib31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":"Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis","volume":"58","author":"Al Mamari","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib32","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2020.07.032","article-title":"Inter- and intra-individual variation, and limited prognostic utility, of serum alkaline phosphatase in a trial of patients with primary sclerosing cholangitis","volume":"19","author":"Trivedi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.27825","article-title":"Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis","volume":"62","author":"Vesterhus","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.010_bib34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib35","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2105\/AJPH.74.9.979","article-title":"Consensus methods: characteristics and guidelines for use","volume":"74","author":"Fink","year":"1984","journal-title":"Am J Publ Health"},{"key":"10.1016\/j.cld.2025.06.010_bib36","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.010_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2021.109884","article-title":"Assessment of prognostic value and interreader agreement of ANALI scores in patients with primary sclerosing cholangitis","volume":"142","author":"Grigoriadis","year":"2021","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.cld.2025.06.010_bib38","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/apt.17944","article-title":"Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: a prospective study","volume":"59","author":"Trivedi","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2025.06.010_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13154548","article-title":"Quantitative magnetic resonance cholangiopancreatography scoring and its predictive value for outcomes in adults with primary sclerosing cholangitis","volume":"13","author":"Mandea","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.cld.2025.06.010_bib40","article-title":"A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis","volume":"5","author":"Vuppalanchi","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2025.06.010_bib41","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.dld.2022.10.015","article-title":"A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis","volume":"55","author":"Cristoferi","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cld.2025.06.010_bib42","article-title":"Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis","volume":"4","author":"Cazzagon","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2025.06.010_bib43","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00535-020-01681-z","article-title":"Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities","volume":"55","author":"Vesterhus","year":"2020","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2036.2011.04966.x","article-title":"High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia","volume":"35","author":"Lindstr\u00f6m","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2025.06.010_bib45","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.06.010_bib46","article-title":"Hormone replacement for osteoporosis in women with primary biliary cirrhosis","author":"Rudic","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cld.2025.06.010_bib47","first-page":"Cd011343","article-title":"Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis","volume":"3","author":"Saffioti","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cld.2025.06.010_bib48","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12016-019-08764-7","article-title":"Cholangiocarcinoma in patients with primary sclerosing cholangitis (PSC): a comprehensive review","volume":"58","author":"Song","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.cld.2025.06.010_bib49","series-title":"Norucholic acid for the treatment of primary sclerosing cholangitis: 96-week analysis of a pivotal phase 3 trial","author":"Trauner","year":"2025"},{"key":"10.1016\/j.cld.2025.06.010_bib50","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S0168-8278(24)00606-8","article-title":"Oral alpha-v\/beta-6 and alpha-v\/beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC phase 2a trial","volume":"80","author":"Trauner","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(25)01010-4","article-title":"CM-101 impacts disease biomarkers in primary sclerosing cholangitis: assessment of the SPRING study pharmacokinetics and pharmacodynamics","volume":"82","author":"Frankel","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.04.025","article-title":"Safety and efficacy of elafibranor in primary sclerosing cholangitis: the ELMWOOD phase II randomized-controlled trial","author":"Levy","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib53","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.010_bib54","first-page":"S411","article-title":"Associations between biomarkers and magnetic resonance imaging-derived anali score in patients with primary sclerosing cholangitis: analysis from the phase 3 primis study","volume":"80","author":"Trauner","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.010_bib55","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0168-8278(23)00454-3","article-title":"A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of cilofexor in patients with non-cirrhotic primary sclerosing cholangitis (PRIMIS)","volume":"78","author":"Trauner","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib56","doi-asserted-by":"crossref","first-page":"S480","DOI":"10.1016\/S0168-8278(20)31439-2","article-title":"Correlation of serum bile acids and pruritus with aldafermin (NGM282) therapy in patients with primary sclerosing cholangitis","volume":"73","author":"Mayo","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib57","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib58","doi-asserted-by":"crossref","first-page":"S386","DOI":"10.1016\/S0168-8278(23)01037-1","article-title":"INTEGRIS-PSC phase 2a study: evaluating the safety, tolerability, and pharmacokinetics of bexotegrast (PLN-74809) in participants with primary sclerosing cholangitis","volume":"78","author":"Hirschfield","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3350\/cmh.2024.0629","article-title":"Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: a randomized double-blind phase 2a trial","volume":"31","author":"Paik","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib61","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1136\/gutjnl-2017-314249","article-title":"Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link?","volume":"66","author":"O'Hara","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cld.2025.06.010_bib62","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41575-019-0125-y","article-title":"Cholangiocyte pathobiology","volume":"16","author":"Banales","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3748\/wjg.v18.i1.1","article-title":"Recurrence and rejection in liver transplantation for primary sclerosing cholangitis","volume":"18","author":"Fosby","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11901-019-00456-2","article-title":"The use of biologics in patients with inflammatory bowel disease and primary sclerosing cholangitis","volume":"18","author":"Lynch","year":"2019","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.cld.2025.06.010_bib65","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000471874","article-title":"Immunosuppressive agents for the treatment of primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"35","author":"Peng","year":"2017","journal-title":"Dig Dis"},{"key":"10.1016\/j.cld.2025.06.010_bib66","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MCG.0b013e3181662426","article-title":"A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis","volume":"42","author":"Hommes","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib67","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/apt.14829","article-title":"Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease","volume":"48","author":"Tse","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2025.06.010_bib68","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/00365520310005172","article-title":"Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients","volume":"38","author":"Boberg","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib69","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1111\/j.1572-0241.2000.02323.x","article-title":"Oral budesonide in the treatment of primary sclerosing cholangitis","volume":"95","author":"Angulo","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib70","first-page":"57","article-title":"The combination of prednisone and colchicine in patients with primary sclerosing cholangitis","volume":"86","author":"Lindor","year":"1991","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib71","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0002-9270(00)01059-5","article-title":"Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC study group","volume":"95","author":"van Hoogstraten","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib72","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib73","doi-asserted-by":"crossref","first-page":"943","DOI":"10.7326\/0003-4819-131-12-199912210-00006","article-title":"Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series","volume":"131","author":"Schramm","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2025.06.010_bib74","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cgh.2018.11.002","article-title":"Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Stokkeland","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib75","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2036.2004.02214.x","article-title":"A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis","volume":"20","author":"Sterling","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2025.06.010_bib76","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1478-3231.2007.01441.x","article-title":"Tacrolimus for the treatment of primary sclerosing cholangitis","volume":"27","author":"Talwalkar","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2025.06.010_bib77","first-page":"455","article-title":"Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial","volume":"90","author":"Van Thiel","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib78","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nrgastro.2015.78","article-title":"Therapy. Statins and liver disease: from concern to \u2019wonder' drugs?","volume":"12","author":"Bosch","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib79","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","article-title":"Cirrhosis as new indication for statins","volume":"69","author":"Bosch","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cld.2025.06.010_bib80","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ijc.33323","article-title":"A potential role for aspirin in the prevention and treatment of cholangiocarcinoma","volume":"148","author":"Shen","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cld.2025.06.010_bib81","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hep.28529","article-title":"Aspirin use and the risk of cholangiocarcinoma","volume":"64","author":"Choi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.010_bib82","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/qjmed\/hcz039","article-title":"Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis","volume":"112","author":"Lapumnuaypol","year":"2019","journal-title":"Qjm"},{"key":"10.1016\/j.cld.2025.06.010_bib83","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.2147\/CMAR.S173197","article-title":"Aspirin use is associated with a reduced risk of cholangiocarcinoma: a systematic review and meta-analysis","volume":"10","author":"Xiong","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.cld.2025.06.010_bib84","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","article-title":"The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls","volume":"66","author":"Kummen","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cld.2025.06.010_bib85","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.cld.2025.06.010_bib86","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/s41564-019-0483-9","article-title":"Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC\/IBD diagnoses","volume":"4","author":"Vieira-Silva","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.cld.2025.06.010_bib87","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-0037-1608801","article-title":"The microbiome in primary sclerosing cholangitis: current evidence and potential concepts","volume":"37","author":"Hov","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cld.2025.06.010_bib88","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile acid metabolites control T(H)17 and T(reg) cell differentiation","volume":"576","author":"Hang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.cld.2025.06.010_bib89","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41385-019-0162-4","article-title":"Emerging roles of bile acids in mucosal immunity and inflammation","volume":"12","author":"Chen","year":"2019","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.cld.2025.06.010_bib90","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/apt.14540","article-title":"Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis","volume":"47","author":"Damman","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2025.06.010_bib91","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-221165","article-title":"Efficacy of oral vancomycin in recurrent primary sclerosing cholangitis following liver transplantation","volume":"2017","author":"Hey","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.cld.2025.06.010_bib93","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/MJT.0000000000000102","article-title":"Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis","volume":"24","author":"Tabibian","year":"2017","journal-title":"Am J Therapeut"},{"key":"10.1016\/j.cld.2025.06.010_bib94","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hep.20457","article-title":"Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial","volume":"40","author":"F\u00e4rkkil\u00e4","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.010_bib95","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ajg.2008.14","article-title":"Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study","volume":"104","author":"Silveira","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib96","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/imj.1965.14.4.286","article-title":"Effect of long-term tetracycline therapy, steroid therapy and colectomy in pericholangitis associated with ulcerative colitis","volume":"14","author":"Mistilis","year":"1965","journal-title":"Australas Ann Med"},{"key":"10.1016\/j.cld.2025.06.010_bib97","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1055\/s-0039-1688501","article-title":"Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis","volume":"39","author":"Shah","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cld.2025.06.010_bib98","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2025.06.010_bib99","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.cld.2025.06.010_bib100","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.clinre.2018.06.009","article-title":"Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience","volume":"42","author":"Lemoinne","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib101","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0140-6736(02)07374-9","article-title":"Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease","volume":"359","author":"Grant","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2025.06.010_bib102","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/MEG.0b013e3282f5197e","article-title":"Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study","volume":"20","author":"Vleggaar","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib103","unstructured":"French D, Huntzicker EG, Goodman ZD, et al. Hepatic expression of lysyl oxidase-like-2 (LOXL2) in primary sclerosing cholangitis (PSC), In Hepatology, WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2016."},{"key":"10.1016\/j.cld.2025.06.010_bib104","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.06.010_bib105","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13063-017-1966-8","article-title":"Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial","volume":"18","author":"Bolier","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.cld.2025.06.010_bib106","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-230X-7-44","article-title":"Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study","volume":"7","author":"Cindoruk","year":"2007","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.010_bib107","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.010_bib108","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fphar.2018.00931","article-title":"Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH","volume":"9","author":"Al-Dury","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cld.2025.06.010_bib109","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1542-3565(03)00134-4","article-title":"Natural history of pruritus in primary biliary cirrhosis","volume":"1","author":"Talwalkar","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib110","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.cgh.2022.10.032","article-title":"GLIMMER: a randomized phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus","volume":"21","author":"Levy","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib111","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.cgh.2022.11.034","article-title":"Treating itch in primary biliary cholangitis: a GLIMMER of hope that needs a nugget of validation","volume":"21","author":"Vuppalanchi","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib112","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.cgh.2022.10.032","article-title":"GLIMMER: a randomized phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus","volume":"21","author":"Levy","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.010_bib113","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/HMER.S361077","article-title":"Primary biliary cholangitis: promising emerging innovative therapies and their impact on GLOBE scores","author":"Sohal","year":"2023","journal-title":"Hepatic Med"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:26:10Z","timestamp":1760855170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125000509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":112,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1089326125000509"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.06.010","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future Treatment Options for Managing Primary Sclerosing Cholangitis and Cholestatic Pruritus","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}